Paraná | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder	Active, not recruiting	Phase 3	2026-09-04		NCT05739383
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma	Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiratory Hypersensitivity, asthma, bronchial disorder, disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder	Active, not recruiting	Phase 2	2026-04-07		NCT07120503
RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Recruiting	Not stated	2024-01-09		NCT05127148
RWE of 1st Line Treatment With ATO/ATRA for Adult APL	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Recruiting	Not stated	2024-01-09		NCT04897490